Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Brukinsa“
Suchtreffer
Begriffe & Kennungen
Brukinsa · 4.5 · CYP2C19 substrates
Eintrag öffnenBrukinsa · 4.5 · CYP2C19 substrates
Eintrag öffnenBrukinsa · 4.5 · CYP3A inducers
Eintrag öffnenBrukinsa · 4.5 · CYP3A inducers
Eintrag öffnenBrukinsa · 4.5 · CYP3A substrates
Eintrag öffnenBrukinsa · 4.5 · CYP3A substrates
Eintrag öffnenBrukinsa · 4.5 · Co-administration of multiple doses of rifampicin (strong CYP3A inducer) decreased zanubrutinib Cmax by 92% an
Eintrag öffnenBrukinsa · 4.5 · Co-administration of multiple doses of rifampicin (strong CYP3A inducer) decreased zanubrutinib Cmax by 92% an
Eintrag öffnenBrukinsa · 4.5 · Co-administration of multiple doses of zanubrutinib decreased midazolam (CYP3A substrate) Cmax by 30% and AUC
Eintrag öffnenBrukinsa · 4.5 · Co-administration of multiple doses of zanubrutinib decreased midazolam (CYP3A substrate) Cmax by 30% and AUC
Eintrag öffnenBrukinsa · 4.5 · Co-administration of multiple doses of zanubrutinib decreased omeprazole (CYP2C19 substrate) Cmax by 20% and A
Eintrag öffnenBrukinsa · 4.5 · Co-administration of multiple doses of zanubrutinib decreased omeprazole (CYP2C19 substrate) Cmax by 20% and A
Eintrag öffnenBrukinsa · 4.5 · Co-administration of multiple doses of zanubrutinib increased digoxin (P-gp substrate) Cmax by 34% and AUC by
Eintrag öffnenBrukinsa · 4.5 · Co-administration of multiple doses of zanubrutinib increased digoxin (P-gp substrate) Cmax by 34% and AUC by
Eintrag öffnenBrukinsa · 4.5 · Co-administration with transport substrates/inhibitors
Eintrag öffnenBrukinsa · 4.5 · Co-administration with transport substrates/inhibitors
Eintrag öffnenBrukinsa · 4.5 · Concomitant use of BRUKINSA and medicinal products that strongly or moderately inhibit CYP3A can increase zanu
Eintrag öffnenBrukinsa · 4.5 · Concomitant use of BRUKINSA and medicinal products that strongly or moderately inhibit CYP3A can increase zanu
Eintrag öffnenBrukinsa · 4.5 · Concomitant use of zanubrutinib and strong or moderate inducers of CYP3A can decrease zanubrutinib plasma conc
Eintrag öffnenBrukinsa · 4.5 · Concomitant use of zanubrutinib and strong or moderate inducers of CYP3A can decrease zanubrutinib plasma conc
Eintrag öffnen